Immunomodulatory effects of HMG-CoA reductase inhibitors

Archivum Immunologiae et Therapiae Experimentalis

Volumn 51, Issue 3, 2003, Pages 139-148

  Danesh, Farhad R ^a   Anel, Ramon L ^a   Zeng, Lixia ^a   Lomasney, Jon ^a   Sahai, Atul ^a   Kanwar, Yashpal S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

HMG CoA reductase inhibitors; Immunomodulation; Inflammation; Transplantation

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COMPACTIN; FLUINDOSTATIN; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; ISOPRENOID; LIPID; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVALONIC ACID; MEVINOLIN; PRAVASTATIN; RAS PROTEIN; SIMVASTATIN; STATINE DERIVATIVE;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CHOLESTEROL SYNTHESIS; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NONHUMAN; OXIDATIVE STRESS; PLEIOTROPY; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0038687621     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. ALBERT M. A., DANIELSON E., RIFAI N. and RIDKER P. M. (2001): Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 286, 64-70.
2. ATKINS D., PSATY B. M., KOEPSELL T. D., LONGSTRETH W. T. JR. and LARSON E. B. (1993): Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomized controlled clinical trials. Ann. Intern. Med., 119, 136-145.
3. BERGE K. G. and CANNER P. L. (1991): Coronary drug project: experience with niacin. Eur. J. Clin. Pharm., 40, S49-51.
4. BLANCO-COLIO L. M., VILLA A., ORTEGO M., HERNANDEZ-PRESA M. A., PASCUAL A., PLAZA J. J. and EGIDO J. (2002): 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis, 161, 17-26.
5. BORGHI C., DORMI A., VERONESI M., IMMORDINO V. and AMBROSIONI E. (2002): Use of lipid-lowering drugs and blood pressure control in patients with arterial hypertension. J. Clin. Hypertens, 4, 277-285.
6. BROWN W. V. (1990): Review of clinical trials: proving the lipid hypothesis. Eur. Heart J., 11 (suppl.), H15-20.
7. BUSTOS C., HERNANDEZ-PRESA M. A., ORTEGO M., TUNON J., ORTEGA L., PEREZ F., DIAZ C., HERNANDEZ G. and EGIDO J. (1998): HMG-CoA reductase inihibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol., 32, 2057-2064.
8. BYINGTON R. P., DAVIS B. R., PLEHN J. F., WHITE H. D., BAKER J., COBBE S. M. and SHEPHERD J. (2001): Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling Project. Circulation, 103, 387-392.
9. CHINETTI G., FRUCHART J. C. and STAELS B. (2000): Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res., 49, 497-505.
10. CUTTS J. L. and BANKHURST A. D. (1989): Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int. J. Immunopharmacol., 11, 863-869.
11. DANESH F. R., SADEGHI M. M., AMRO N., PHILIPS C., ZENG L., LIN S., SAHAI A. and KANWAR Y. S. (2002): 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc. Natl. Acad. Sci. USA, 99, 8301-8305.
12. DAVIGNON J. and MABILE L. (2001): Mechanisms of action of statins and their pleiotropic effects. Ann. Endocrinol., 62, 101-112.
13. DOWNS J. R., CLEARFIELD M., WEIS S., WHITNEY E., SHAPIRO D. R., BEERE P. A., LANGENDORFER A., STEIN E. A., KRUYER W. and GOTTO A. M. JR. (1998): Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol: results of the AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279, 1615-1622.
14. DOWNWARD J. (1998): Ras signaling and apoptosis. Curr. Opin. Genet. Dev., 8, 49-53.
15. DURIEZ P. (2001): Current practice in the treatment of hyperlipidaemias. Expert Opin. Pharmacother., 2, 1777-1794.
16. EDWARDS C. J. and SPECTOR T. D. (2002): Statins as modulators of bone formation. Arthritis Res., 4, 151-153.
17. ENDO A., KURODA M. and TSUJITA Y. (1976): ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillum citrinum. J. Antibiot. (Tokyo), 29, 1346-1348.
18. EVANS M. and REES A. (2002): Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf., 25, 649-663.
19. FOLSOM A. R., ALEKSIC N., CATELLIER D., JUNEJA H. S. and WU K. K. (2002): C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. Am. Heart J., 144, 233-238.
20. GANNE F., VASSE M., BEAUDEUX J. L., PEYNET J., FRANCOIS A., MISHAL Z., CHARTIER A., TOBELEM G., VANNIER J. P., SORIA J. and SORIA C. (2000): Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb. Haemost., 84, 680-688.
21. GAW A. (2002): A new reality: achieving cholesterol-lowering goals in clinical practice. Atherosclerosis, 2, S5-S8.
22. GOLDSTEIN J. L. and BROWN M. S. (1990): Regulation of the mevalonate pathway. Nature, 343, 425-430.
23. GOTTO A. M. JR. and FARMER J. A. (2002): Reducing the risk for stroke in patients with myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation, 106, 1595-1598.
24. GRIP O., JANCIAUSKIENNE S. and LINDGREN S. (2000): Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur. J. Pharmacol., 410, 83-92.
25. GUYTON J. R. (1998): Effect of niacin on atherosclerotic cardiovascular disease. Am. J. Cardiol., 82, 18U-23U.
26. HATANAKA T. (2000): Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events. Clin. Pharmacokinet., 39, 397-412.
27. HAYRY P. (1998): Chronic allograft vasculopathy: new strategies for drug development. Transplant. Proc., 30, 3989-3990.
28. Heart Protection Study Collaborative Group (2002): MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized, placebo-controlled trial. Lancet, 360, 7-22.
29. HENRY R. Y. and KENDALL M. J. (1998): Does cholesterol lowering prevent stroke? J. Clin. Pharm. Ther., 23, 337-344.
30. HESS D. C. and FAGAN S. C. (2001): Pharmacology and clinical experience with simvastatin. Expert Opin. Pharmacother., 2, 153-163.
31. IGEL M., SUDHOP T. and VON BERGMANN K. (2001): Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur. J. Clin. Pharmacol., 57, 357-364.
32. IKEDA U., SHIMPO M., IKEDA M., MINOTA S. and SHIMADA K. (2001): Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J. Cardiovasc. Pharmacol., 38, 69-77.
33. INOUE I., GOTO S., MIZOTANI K., AWATA T., MASTUNAGA T., KAWAI S., NAKAJIMA T., HOKARI S., KOMODA T. and KATAYAMA S. (2000): Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPAR α) in primary endothelial cells. Life Sci., 67, 863-876.
34. IZUMO N., FUJITA T., NAKAMUTA H. and KOIDA M. (2001): Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner. Methods Find. Exp. Clin. Pharmacol., 23, 389-394.
35. JOHNSON M. R. (1992): Transplant coronary disease: non-immunologic risk factors. J. Heart Lung Transplant., 11, S124-132.
36. JOUKHADAR C., KLEIN N., PRINZ M., SCHROLNBERGER C., VUKOVICH T., WOLZT M., SCHMETTERER L. and DORNER G. T. (2001): Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb. Haemost., 85, 47-51.
37. KATZNELSON S. and KOBASHIGAWA J. A. (1995): Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosupression. Kidney Int. Suppl., 52, 12-115.
38. KEARNEY D. and FITZGERALD D. (1999): The anti-thrombotic effects of statins. J. Am. Coll. Cardiol., 33, 1305-1307.
39. KIENER P. A., DAVIS P. M., MURRAY J. L., YOUSSEF S., RANKIN B. M. and KOWALA M. (2001): Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int. Immunopharmacol., 1, 105-118.
40. KIM S. I., KIM H. J., HAN D. C. and LEE H. B. (2000): Effect of lovastatin on small GTP binding proteins and on TGF-β1 and fibronectin expression. Kidney Int. Suppl., 77, S88-92.
41. KITAGAWA-SAKAKIDA S., TORI M., LI Z., HORIGUCHI K., IZUTANI H., MATSUDA H. and SHIRAKURA R. (2000): Active cell migration in retransplanted rat cardiac allografts during the course of chronic rejection. J. Heart Lung Transplant., 19, 584-590.
42. KNAPP A. C., HUANG J., STARLING G. and KIENER P. A. (2000): Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis, 152, 217-227.
43. KOBASHIGAWA J. A., KATZNELSON S., LAKS H., JOHNSON J. A., YEATMAN L., WANG X. M., CHIA D., TERASAKI P. I., SABAD A., COGERT G. A. et al. (1995): Effect of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med., 333, 621-627.
44. KORLIPARA K. (2002): Statin therapy: rationale for a new agent, rosuvastatin. Int. J. Clin. Pract. 56, 379-387.
45. KOTHE H., DALHOFF K., RUPP J., MULLER A., KREUZER J., MAASS M. and KATUS H. A. (2000): Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation, 101, 1760-1763.
46. KREUZER J., BADER J., JAHN L., HAUTMANN M., KUBLER W. and VON HODENBERG E. (1991): Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis, 90, 203-209.
47. KURAKATA S., KADA M., SHIMADA Y., KOMAI T. and NOMOTO K. (1996): Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology, 34, 51-61.
48. KUSHNER I. (2001): C-reactive protein elevation can be caused by conditions other than inflammation and may reflect biologic aging. Cleve Clin. J. Med., 68, 535-537.
49. KWAK B., MULHAUPT F., MYIT S. and MACH F. (2000): Statins as a newly recognized type of immunomodulator. Nat. Med., 6, 1399-1402.
50. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998): Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339, 1349-1357.
51. MAEDA T., MATSUNUMA A., KAWANE T. and HORIUCHI N. (2001): Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem. Biophys. Res. Commun., 280, 874-877.
52. MAGGARD M. A., KE B., WANG T., MARKOWITZ J. S., MAGGARD M. A., SPEAR G. S., IMAGAWA D. K., GOSS J. A., BUSUTTIL R. W. and SEU P. (1998): Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation, 65, 149-155.
53. MATTINGLY R. R., GIBBS R. A., MENARD R. E. and REINERS J. (2002): Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase. J. Pharmacol. Exp. Ther., 303, 74-81.
54. MOHLER E. R., DELANTY N., RADER D. J. and RAPS E. C. (1999): Statins and cerebrovascular disease: plaque attack to prevent brain attack. Vasc. Med., 4, 269-272.
55. MUNDY G., GARRETT R., HARRIS S., CHAN J., CHEN D., ROSSINI G., BOYCE B., ZHAO M. and GUTIERREZ G. (1999): Stimulation of bone formation in vitro and in rodents by statins. Science, 286, 1946-1949.
56. MUSIAL J., UNDAS A., GAJEWSKI P., JANKOWSKI M., SYDOR W. and SZCZEKLIK A. (2001): Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int. J. Cardiol., 77, 247-253.
57. NISHIO E., TOMIYAMA K., NAKATA H. and WATANABE Y. (1996): 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor impairs cell p4fferentiation in cultured adipogenic cells (3T3-L1). Eur. J. Pharmacol., 301, 203-206.
58. NIWA S., TOTSUKA T. and HAYASHI S. (1996): Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int. J. Immunopharmacol., 18, 669-675.
59. PAHAN K., SHEIKH F. G., MANBOODIRI A. M. and SINGH I. (1997): Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest., 100, 2671-2679.
60. PALINSKI W. (2000): Immunomodulation: a new role for statins? Nat. Med., 6, 1311-1312.
61. PARK Y. S., GUIJARRO C., KIM Y., MASSY Z. A., KASISKE B. L., KEANE W. F. and O'DONNELL M. P. (1998): Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephritic rats. Am. J. Kidney Dis., 31, 190-194.
62. PASCERI V., CHANG J., WILLERSON J. T. and YEH E. T. (2001): Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation, 103, 2531-2534.
63. PORTER K. E., NAIK J., TURNER N. A., DICKINSON T., THOMPSON M. M. and LONDON N. J. (2002): Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration. J. Vasc. Surg., 36, 150-157.
64. RIDKER P. M., RIFAI N., CLEARFIELD M., DOWNS J. R., WEIS S. E., MILES J. S. and GOTTO A. J. JR. (2001): Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 344, 1959-1965.
65. RIDKER P. M., RIFAI N., PFEFFER M. A., SACKS F. and BRAUNWALD E. (1999): Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 100, 230-235.
66. RIDKER P. M., RIFAI N., PFEFFER M. A., SACKS F. M., MOYE L. A., GOLDMAN S., FLAKER G. C. and BRAUNWALD E. (1998): Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 98, 839-844.
67. ROMAN M., DIOMEDE L., SIRONI M., MASSIMILIANO L., SOTTOCORNO M., POLENTARUTTI N., GUGLIELMOTTI A., AlBANI D., BRUNO A., FRUSCELLA P., SALMONA M., VECCHI A., PINZA M. and MANTOVANI A. (2000): Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest., 80, 1095-1100.
68. ROSENSON R. S., TANGNEY C. C. and CASEY L. C. (1999): Inhibition of proinflammatory cytokine production by pravastatin. Lancet, 353, 983-984.
69. ROSS R. (1999): Atherosclerosis - an inflammatory disease. N. Engl. J. Med., 340, 115-126.
70. ROTHE G., HERR A. S., STOHR J., ABLETSHAUSER C., WEIDINGER G. and SCHMITZ G. (1999): A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis, 144, 251-261.
71. SACKS F. M., PFEFFER M. A., MOYE L. A., ROULEAU J. L., RUTHERFORD J. D., COLE T. G., BROWN L., WARNICA J. W., ARNOLD J. M., WUN C. C., DAVIS B. R. and BRAUNWALD E. (1996): The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001-1009.
72. SADEGHI M. M., TIGLIO A., SADIGH K., O'DONNELL L., COLLINGE M., PRDI R. and BENDER J. R. (2001): Inhibition of interferon-γ-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitor. Transplantation, 71, 1262-1268.
73. Scandinavian Simvastatin Survival Study Group (1994): Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
74. SHEPHERD J., COBBE S. M., FORD I., ISLES C. G., LORIMER A. R., MACFARLANE P. W., MCKILLOP J. H. and PACKARD C. J. (1995): Study Group. Prevention of coronary heart disease in men with hypercholestrolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 333, 1301-1307.
75. SOTIRIOU C. G. and CHENG J. W. (2000): Beneficial effects of statins in coronary artery disease - beyond lowering cholesterol. Ann. Pharmacother., 34, 1432-1439.
76. SPARROW C. P., BURTON C. A., HERNANDEZ M., MUNDT S., HASSING, H., PATEL S., ROSA R., HERMANOWSKI-VOSATKA A., WANG P. R., ZHANG D., PETERSON L., DETMERS P. A., CHAO Y. S., and WRIGHT S. D. (2001): Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler. Thromb. Vasc. Biol., 21, 115-121.
77. SPEIDL W. S., GRAF S., HORNYKEWYCZ S., NIKFARDJAM M., NIESSNER A., ZORN G., WOJTA J. and HUBER K. (2002): High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. Am. Heart J., 144, 449-455.
78. STEIN E. (2002): The lower the better? Reviewing the evidence for more aggressive cholesterol reduction and goal attainment. Atherosclerosis, 2, S19-23.
79. TAKEMOTO M. and LIAO J. K. (2001): Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol., 21, 1712-1719.
80. TEO K. K. and BURTON J. R. (2002): Who should receive HMG CoA reductase inhibitors? Drugs, 62, 1707-1715.
81. The Prospective Studies Collaboration (1995): Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 455,000 people in 45 prospective cohorts. Lancet, 346, 1647-1653.
82. VALANTINE H. A. (1998): Do calcium channel blockers and HMG-CoA reductase inhibitors attenuate allograft arteriopathy? Curr. Opin. Cardiol., 13, 111-116.
83. VAN AELST L. and D'SOUZA-SCHOREY C. (1997): Rho GTPase and signaling networks. Genes Dev., 11, 2295-2322.
84. VESELKA J., PROCHAZKOVA S., DUCHONOVA R., BOLOMOVA I., URBANOVA T., TESAR D. and HONEK T. (2002): Relationship of C-reactive protein to presence and severity of coronary atherosclerosis in patients with stable angina pectoris or a pathological exercise test. Coron. Artery Dis., 13, 151-154.
85. VINCENT L., SORIA C., MIRSHAHI F., OPOLON P., MISHAL Z., VANNIER J. P., SORIA J. and HONG L. (2002): Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler. Thromb. Vasc. Biol., 22, 623-629.
86. WEBER C., ERL W., WEBER K. S. and WEBER P. C. (1997): HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated form patients with hypercholesterolemia. J. Am. Coll. Cardiol., 30, 1212-1217.
87. WEBER C., ERL W. and WEBER P. C. (2001): Lovastatin induces differentiation of Mono Mac 6 cells. Cell. Biochem. Funct., 13, 273-277.
88. WEI X., SI M. S., IMAGAWA D. K., JI P., TROMBERG B. J. and CAHALAN M. D. (2000): Perillyl alcohol inhibits TCR-mediated [Ca(2+)] (i) signaling, alters cell shape and motility, and induces apoptosis in T lymphocytes. Cell. Immunol., 201, 6-13.
89. WEIS M., HEESCHEN C., GLASSFORD A. J. and COOKE J. P. (2002): Statins have biphasic effects on angiogenesis. Circulation, 105, 739-745.
90. WEITZ-SHMIDT G., WELZENBACH K., BRINKMANN V., KAMATA T., KALLEN J., BRUNS C., COTTENS S., TAKADA Y. and HOMMEL U. (2001): Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med., 7, 687-692.
91. WIERZBICKI A. S. (2001): Atorvastatin. Expert Opin. Pharmacother., 2, 819-830.
92. Xu C. B., STENMAN E. and EDVINSSON L. (2002): Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem. Pharmacol., 64, 497-505.